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Background: Chronic obstructive pulmonary disease (COPD) can lead to peripheral muscle
atrophy and weakness. Electrical stimulation (ES) is commonly used to improve muscle function
and structure. The purpose of this systematic review is to determine the effect of ES on muscle
function, muscle size, fibre characteristics and exercise performance in patients with COPD.
Methods: A search was performed in seven electronic databases (Cochrane Controlled Trials
Register, Pubmed, CINAHL, Embase, SPORTDiscus, Web of Science, PEDro). Inclusion criteria
were: (1) randomized controlled trials (RCTs), (2) on COPD patients, (3) investigating a defined
protocol of ES applied to the lower extremities, (4) analysing at least one main outcome, (5) full
text available. Two reviewers extracted thedataandevaluated themethodological quality of the
studies using the PEDro scale.
Results: The initial search yielded 167 abstracts, of which five RCTs met the inclusion criteria.
The mean (SD) methodological quality of the studies was 6.2 þ 1.3 out of 10. Meta-analyses of
three studies showed significant increases in muscle torque and walk distance in the ES groups
compared to values in the control, sham or other treatment groups. Measures of muscle size re-
vealed equivocal evidence. Patients with less severe COPD tended to show less improvement.
Conclusions: Themodest effect sizes after ES, small n, and small number of studies provideweak
evidence for the effectiveness of ES to improve lower limb muscle function in COPD patients.
Further study should elucidate the optimal parameters for ES protocols and selection criteria
for responders and non-responders.
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Chronic obstructive pulmonary disease (COPD) is character-
ized by progressive, partially reversible airflow limitation,
which results from an emphysematous destruction of the lung
parenchyma and an increased airway resistance due to infla-
mmation and fibrosis, bronchospasm and increased mucous
production. Although formerly considered a disease that
mainly results in pulmonary impairment, it is now recognized
that people living with COPD have many systemic manifesta-
tions including peripheral muscle dysfunction,1 right-sided
heart failure, malnutrition and depression.2 Thus, multiple
mechanisms contribute to exercise limitation in COPD.3
People with COPD are more commonly limited during
exercise by limb fatigue or limb fatigue and dyspnea than
dyspnea alone.4 Weakness, atrophy, structural and meta-
bolic changes have been observed in limb muscles, which in
turn, can have a negative impact on exercise tolerance.5e9
Peripheral muscle dysfunction in people with COPD is
characterized by: (i) reduced percentage of the oxidative
fibres (type I) in relation to glycolytic fibres (type IIa and
IIb);10e13 (ii) decreased activity of most oxidative enzymes
while glycolytic enzyme expression is increased;7 (iii)
reduced capillary density or capillary-to-fibre ratio;14 and
(iv) mitochondrial dysfunction.15 Taken together, these
changes contribute to an overall reduction in the oxidative
capacity of the muscles of patients with COPD.
Pulmonary rehabilitation is the cornerstone of any treat-
ment protocol for patients with COPD as outlined by recent
national and international guidelines on COPD manage-
ment.16e19 Exercise protocols have traditionally focussed on
aerobic training in pulmonary rehabilitation programs,
however, more recently, increased emphasis has been placed
on resistive training because of the importance ofmaintainingor improving muscle bulk and strength in this group of
patients.20e22 Unfortunately, some debilitated patients with
COPD are unable to sustain an adequate training intensity and
durationbecauseof the rapidonsetof fatigueduring the initial
stages of the exercise. This normally leads to reduced activity
or even to the patient being confined to their home or bed,
thus accentuating the deterioration of the overall health
status of this individual. Recently, several investigations have
reported the benefit of using electrical stimulation (ES) to
reverse some of the negative changes occurring in the
peripheral muscles of patients with COPD.23e28
ES has been extensively used as a technique to improve
muscle function and structure in different areas of reha-
bilitation29e31 and sports training.32,33 Even though ES has
been shown to play an important role in ameliorating
muscle loss, increasing protein turnover, and also in
conserving oxidative muscle function in humans,34e36 there
is no consensus regarding the potential benefits of ES in
patients with COPD. We performed a systematic review to
determine the effectiveness of this technique to induce
structural and functional improvements in the lower limb
muscles of these patients. The main outcomes analysed in
the present study include muscle function, muscle size,
fibre type characteristics and exercise performance.Method
Search strategy
A literature search was performed on the following
databases: Cochrane Controlled Trials Register, Pubmed
(1949epresent), CINAHL (1982epresent), Embase (1980e
present), SPORTDiscus (1830epresent), Web of Science,
Electrical stimulation and muscle function in COPD 487PEDro. Reference lists from articles related to the topic
were also searched. Only published studies written in
English were included. The text words used to perform the
search were ‘‘electrotherapy’’, ‘‘electrical stimulation’’
and ‘‘neuromuscular electrical stimulation’’. The results of
these primary searches were then combined with the
following text words: ‘‘chronic obstructive pulmonary
disease’’. Titles and abstracts of the articles were retrieved
and reviewed by the first author who selected only those
that met the inclusion criteria.
Study selection
Inclusion criteria were (1) randomized controlled trials
(RCTs) investigating the potential role of ES in patients with
COPD; (2) a specific and well defined component of ES for at
least one intervention group; (3) ES was applied to the
lower extremities; (4) one or more of the following
outcomes were included: muscle function, muscle size,
muscle fibre characteristics and exercise performance; (5)
full text was available.
Data extraction and quality assessment
Both authors extracted the data from the studies identified
in the computerized search. The following details were
extracted: study design, participant characteristics, inter-
ventions, outcomes (pre and post intervention scores) and
statistical methodology. Methodological quality of the
studies was assessed by both authors using the PEDro
scale.37 The PEDro scale contains items well suited to
evaluate studies within the realm of rehabilitation and it
has shown good reliability in previous studies.38,39 This
scale was originally adapted from the Delphi list for quality
assessment of RCTs conducting systematic reviews40 and it
is based on the following 11 items regarding scientific rigor:
eligibility criteria, random allocation, concealed alloca-
tion, follow-up, baseline comparability, blinded subjects,
blinded therapists, blinded assessors, intention to treat,
between group analysis, and both point measures and
measures of variability. All except one item (eligibility
criteria) were used to calculate the final score (maximum
10 points). This item was excluded because it affects
external but not internal or statistical validity.37 In order to
evaluate the reliability of the scores, the methodological
quality of the selected articles was independently assessed
by two reviewers.41 Agreement between reviewers was
assessed as the percentage of the total items scored. In the
case of disagreement, a third reviewer was included in the
discussion to reach a final consensus.
Data analysis
The effect size for comparable outcome measures was
calculated in order to determine the relative impact of ES on
muscle function, muscle size, fibre characteristics and
exercise performance in COPD. First, outcomes were grou-
ped in categories of similar features. Muscle function
included measures of peak torque, muscle strength and
isometric strength; muscle size included measurements of
corrected thigh circumference and thigh muscle mass; fibrecharacteristics includedmusclefibrecross sectional areaand
fibre type proportions; exercise performance included
walking distance and time to exhaustion. For each study, the
mean change score (post intervention scores  pre inter-
vention scores) for the main outcomes was calculated. In
addition the pooled standard deviation (SD) was extracted
from thebaseline SD of each group.42Whenonly the standard
error (SE)was provided, SDwas calculated bymultiplying the
SEby the root square of thenumber of participants (SEZ SD/
n).41 The effect size index (d ) was defined as the degree of
differences between groups and it was calculated by dividing
the difference between mean change scores of the experi-
mental (ES) and control groups by the pooled SD.43 The
different levels of interpretation of the effect size index
were categorized according to the criteria established by
Cohen: large effect (0.8), moderate effect (<0.8 but
>0.2), small (0.2).43 The 95% confidence interval (CI) for
the effect sizes was calculated using a custom spreadsheet
(Microsoft Excel for Mac OS 10.1.5).
Meta-analyses were performed with the software RevMan
for Mac O.S (available at http://www.cc-ims.net/RevMan).
Due to the heterogeneity of outcomes and the small number
of studies, meta-analyses were only performed on peak
torque and walking distance. A general random effect anal-
ysis mode (inverse-variance weighted method) that
combined mean differences was used. Forest plots with
mean differences and random pooled effects with the 95% CI
areprovided. Ap < 0.05was selectedas indicating statistical
significance between groups and a p < 0.10 was set to indi-
cate heterogeneity between studies. Effect sizes and quali-
tative descriptions are provided on data that could not be
analysed by performing meta-analyses.
Results
Articles retrieved
A flow chart describing the different phases of the search
process is shown in Fig. 1.
The primary search strategy yielded a large number of
studies (nZ 167). Nevertheless, many of the articles
initially retrieved (nZ 110) were excluded because neither
the title nor the abstract contained relevant information
regarding the topic of the review. Some studies (nZ 44)
were subsequently excluded because of duplicates. When
inclusion criteria were applied, five studies were excluded
due to their design,44e48 two studies were not written in
English46,47 and full text was not available for one report.27
Worthy of note, three of the studies excluded44,45,48 were
reviews summarizing some of the findings extracted from
the RCTs finally included in this review. In addition, one
article written in French46 was a letter of response related
to a previous report. Finally, five studies met the criteria to
be reviewed.23e26,28
Methodological quality
PEDro scores for each study are reported in Table 1. Using
this scale, the mean methodological quality of the studies
was 6.2  1.3 (range: 5e8). The most common flaws were
the lack of blinding of subjects, therapists and assessors,
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Figure 1 Flow chart with different phases of the search
process.
488 M. Roigand no explicit mention of an intention to treat analysis.
Furthermore, allocation was not concealed in all but one23
of the studies evaluated. When scores were compared,
agreement between reviewers was high (94% inter-rater
agreement).
Participants
Demographics of the participants of the studies included
in the systematic review are shown in Table 2. Sample
size ranged from six to 12 patients per group. According
to the GOLD criteria,16 the mean forced expiratory
volume (FEV1) of participants in most studies indicated
severe or very severe COPD.23,26,28 One report25 did not
provide spirometric measures but stated entry criteria
was chronic hypercapnic respiratory failure. Thus, these
patients likely had disease consistent with very severe
COPD. Worthy of note, the study by Dal Corso et al.24 had
participants with a mean FEV1 indicative of Stage II
Moderate COPD. These patients also showed higher
baseline values in walking distance and muscle strength
compared to the subjects enrolled in the other studies.
The mean body mass index (BMI) of the patients usually
fell within the normal range, however, the report by
Vivodtzev et al.28 examined patients with a low BMI
(18.0  2.5 kg/m2). All but one study25 examined patients
who were ambulatory.
Interventions
The characteristics of interventions and the main results
obtained in each study are outlined in Table 3. Two inves-
tigations compared ES to a sham group24,26 and in two
reports, ES was assessed as an adjunct to standard
exercise25 or rehabilitation treatment.28 The fifth study
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Electrical stimulation and muscle function in COPD 489performed a randomized cross-over design whereby ES was
compared to a control/standard treatment.23 In all studies,
ES was applied to the quadriceps muscle and some reports
also examined the effect of ES on the hamstrings and calf
muscles,26 or the glutei.25 Pulse duration ranged from 200
to 400 ms, and stimulation frequency ranged from 8 to
50 Hz. Intensities ranged from 10 to 120 mA and were
progressively increased throughout the study according to
the patient’s individual tolerance. One study did not
provide specific information about the intensity of the ES
protocol implemented.25 The number of ES sessions ranged
from 3 to 5 days per week. All but one study applied ES with
the knee positioned at a fixed knee angle and patients were
asked not to voluntarily contract their muscles during the
ES. In the other study, ES was provided while the patient
was performing assisted limb mobilization.25 The ES, sham
intervention, or control phase was applied for durations
ranging from 4 to 6 weeks. Although in one study,23 two
patients reported mild exacerbations of COPD during the ES
protocol, no adverse effects specific to ES were reported in
any of the studies, which might indicate that the ES therapy
was well tolerated by patients with COPD.Outcomes
Four of the five studies reported improvements of the ES
groups in outcomes related to muscle function compared to
baseline levels and control groups.23,25,26,28 Peak torque
was assessed in three studies in which effect sizes were
small,24 moderate,26 and large23 (Table 4). A meta-analysis
on the pooled data showed that ES groups demonstrated
a greater improvement in peak torque compared to control
groups (Fig. 2) (mean differenceZ 9.64 N m; 95% 1.23e
18.05; pZ 0.02). Isometric strength was evaluated in two
studies in which effect sizes were moderate23,28 (Table 4).
No meta-analyses were performed on the isometric
strength data because the units of measure differed
between studies. In the remaining study, gains in strength
based on a five point grading scale demonstrated a large
effect size25 (Table 4).
Muscle mass or fat-free mass, assessed in only two
studies, did not change23,24 (Table 4). Corrected thigh
circumference increased significantly (p < 0.04) in one
report but the effect size was small28 (Table 4). The study
that assessed muscle fibre characteristics after ES24 found
an increase in the cross sectional area of type II fibres
countered by a decrease in the cross sectional area of type I
fibres (p < 0.05) (Table 4). Capillary density and muscle
fibre type proportions did not change after ES.24
Exercise performance, evaluated by walk tests or
endurance time on a cycling test tended to increase.
Three RCTs analysed the effects of ES on walking
distance. Effect sizes for this outcome were small,24
moderate,28 and large26 (Table 4). A meta-analysis on the
pooled data demonstrated that ES has a significant effect
on walking distance compared to the control group
(Fig. 3) (mean differenceZ 47.55 m; 95% CI 9.08e86.01;
pZ 0.02). The study that assessed exercise improvements
by measuring time to exhaustion during a constant work
rate test demonstrated a large effect size in favour of
ES23 (Table 4).
Table 3 Interventions and results of the studies included in the systematic review.
Study Groups and interventions Parameters of stimulation Results
Control, Sham, or other
treatment
ES treatment
Zanotti25 Ex: ALMs (5 days 
week  4 weeks)
ES-Ex: ALMs þ ES to
quadriceps and vastus glutei:
300  5 days  week  4 weeks
Frequency:8e35 Hz.
Pulses: 250e350 ms.
Intensity: progressively
increased
ES increased s ength (p < 0.02) and had a lower number
of days to tra fer from bed to chair (p < 0.001) compared to
Con
Bourjeily-
Habr26
Sham ES ES: ES quadriceps,
hamstrings, calf muscles: 200
 3 days  week  6 weeks
Frequency:50 Hz.
Pulses: 200 ms every
1500 ms.
Intensity: 50e120 mA
ES improved m re quadriceps (p < 0.046) and hamstrings
(p < 0.038) st gth compared to Con.
Walking distan was increased in ES (p < 0.007) compared
Con
Neder23 Con then ES: 6 weeks of
control period
followed by ES
ES: ES applied to quadriceps:
from 150 in week 1e300in
weeks 2e6; 5 days 
week  6 weeks
Frequency:50 Hz.
Pulses: 300e400 ms.
Intensity: 10/20 mA
up to 100 mA
ES improved m re in peak torque (p < 0.05), muscle fatigue
(p < 0.05) and ndurance capacity (p < 0.05) compared to
Con-ES
Vivodtzev28 Ex: ALMs þ walking þ arm-
lifting 2.5
kg (50e100): 4 days 
week  4 weeks
ES and Ex: as for Ex plus ES
to quadriceps applied for 300
per day  4 days  week  4
weeks
Frequency:5e35 Hz.
Pulses: 400 ms.
Intensity:15 mA up to
90 mA
ES and Ex imp ved significantly more than Ex in MVC
(p < 0.03), BM p < 0.03), walking distance (p < 0.01), and
corrected thig circumference (p < 0.04) compared to Ex
Dal Corso24 Sham ES ES Phase: ES quadriceps:
progressively increasing
duration from 150 at week 1 to
600at weeks 5e6; 5 days 
week 
6 weeks
Sham phase
frequency: 10
Hz. Pulses: 50
ms. Intensity: 10
mA. ES phase
Frequency: 50
Hz. Pulse: 400
ms. Intensity:
10/25 mA up to
45 mA
Type II muscle bre CSA increased but type I CSA
decreased (p 0.05) after ES.
No significant fferences were observed in peak torque,
muscle mass, d walking distance between groups
Groups and interventions: Con, control group; Ex, standard exercise group; ES, electrical stimulation group; ALMs, active limb mobi ations.
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Table 4 Main outcome measures and effect sizes.
Main outcome Outcome measures Effect Size (CI)a
Muscle performance Peak torque 0.19 (0.77e1.14) (Dal Corso)24
0.85 (0.30e1.84) (Neder)23
0.36 (0.58e1.28) (Bourjeily-Habr)26
0.72 (0.26e1.64) (Bourjeily-Habr)26
Isometric strength 0.26 (0.79e1.29) (Neder)25
0.35 (0.63e1.28) (Vivodtzev)28
Strength scoreb 1.24 (0.33e2.07) (Zanotti)25
Muscle size Corrected thigh circumference 0.10 (1.05e0.85) (Vivodtzev)28
Thigh muscle mass 0.17 (0.79e1.11) (Dal Corso)24
CSA of type I fibres 0.383 (0.31e1.05) (Dal Corso)24
CSA of type II fibres 0.299 (0.39e0.96) (Dal Corso)24
Exercise performance Walking distance 0.13 (0.83e1.08) (Dal Corso)24
0.30 (0.67e1.25) (Vivodtzev)28
1.29 (0.20e2.20) (Bourjeily-Habr)26
Time to exhaustion (cycling) 2.30 (0.86e3.44) (Neder)23
CSA, cross sectional area.
a Effect size was calculated by dividing the difference between group means by the pooled standard deviation of the groups.42 The
different levels of interpretation of this index were categorized according to the criterion established by Cohen: large effect (0.8),
moderate effect (<0.8 but >0.2), small (0.2)43.
b Based on a five point grading scale.
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The main findings of this systematic review are that ES
applied to the lower limbs of people with COPD resulted in
moderate improvements in muscle function and exercise
performance compared to the control, sham or other
treatment groups. Although the meta-analysis demon-
strated that peak torque and walking distance were
significantly increased after ES (pZ 0.02), data from indi-
vidual studies had CI that crossed zero, which in part may
be due to variability in individual treatment response.41
Only one report28 found an increase in muscle size after ES.
However, the 95% CI for the effect size also crossed zero
indicative of a large variance. Muscle fibre characteristics,
evaluated in only one study24 reflected reciprocal changes;
the cross sectional area of type II and type I muscle fibres
increased or decreased, respectively. Worthy of note,
a study that examined ES in patients with more moderate
COPD, failed to show improvement in any of the outcomes
analysed.24 According to the PEDro rating system, the
scientific rigor of the studies was variable (scores ranged
from 5 to 8), with no apparent relationship between theFigure 2 Forest plot for meta-analysis of electrical stimevidence of effectiveness of ES and methodological
quality.
Muscle function
Muscle function increased significantly as demonstrated by
the meta-analysis on muscle torque of three reports23,24,26
and the strength measures of a fourth study25 (Table 4,
Fig. 2). Whether these data are indicative of a clinically
meaningful difference is difficult to evaluate due to the
lack of data on what represents a clinically important
increase in muscle torque in COPD patients. Compared to
voluntary training, however, improvements of muscle
function induced by ES were small (mean effect
sizeZ 0.57; range: 0.26e1.74) whereas a recent meta-
analysis exploring the effects of resistance training in
patients with COPD yielded larger effect sizes in lower limb
strength (0.90; 95% CI 0.42e1.38).49 Nonetheless, this fact
does not rule out the potential benefit of ES to preserve
muscle function in patients unable to perform voluntary
work or with reduced mobility such as those confined to
bed. Whether ES can be used as an adjunct of resistance orulation (ES) vs. control group on peak torque (N m).
Figure 3 Forest plot for meta-analysis of electrical stimulation (ES) vs. control group on walking distance (m).
492 M. Roigendurance training, or as an intervention in the initial
phases of training to ‘‘prepare’’ the muscle after immobi-
lization, requires more investigation.
We postulate that, similar to resistance training,50,51
neural adaptations might play an important role in the early
gains in muscle performance observed after ES. We attribute
the improvement to neural remodelling because of the
relatively short duration of the interventions (4e6 weeks),
supporting other studies on ES in the literature, aswell as the
modest increases in muscle mass reported in only one
study.28 Contrary to the traditional view that ES activates
muscles without involving the central nervous system (CNS),
recent studies provide evidence of neural adaptations
resulting from ES.33 Such findings include studies that show
increased strength in the contra-lateral, non-stimulated
limb (cross education effect);52 increased agonist activation
without significant changes inmusclemass;53 doseeresponse
brain activation when ES is applied to lower limb muscles.54
Future studies that utilize twitch interpolation technique or
electromyography53 might further elucidate the potential
contribution of neural mechanisms to the moderate
increases of muscle function observed after ES in COPD.
Very different effect sizes for measures of muscle func-
tion were demonstrated for the five studies, which might be
attributed to the differences in disease severity of partici-
pants and variations in protocols of ES. The one study that
did not find improvements in muscle peak torque after ES28
examined patients with more moderate COPD and a higher
baseline exercise capacity.24 This finding is consistent with
findings of a systematic review that found poormuscle status
(e.g.,muscleweakness) to be an important prognostic factor
for the effectiveness of ES.55 The study that demonstrated
the largest effect sizes in strength gains, applied ESwhile the
patient was performing assisted limb mobilization,25 which
reflects the perspective of a recent review that states that
ES and voluntary contractions might provide more benefit
that either alone.56
Different parameters of ES might provide further
explanation for the variability of muscle strength changes
induced by this intervention. The lowest maximal intensity
of the ES (45 mA) was used by Dal Corso et al.24 who
reported no improvement in peak torque. This is in contrast
to the other studies whose maximum intensities ranged
from 90 to 120 mA.23,26 Although the intensity of ES
contributes significantly to muscle gains57 other stimulation
parameters may play a role as well such as the duty cycle,
which is defined as the ratio of contraction time versus
total time (for relaxation and contraction). Dal Corso
et al.24 used a low intensity and low duty cycle (16e33%)
whereas Vivodtzev et al.28 used comparable low intensities(21  6 to 46  24 mA) but a higher duty cycle (47%) that
resulted in significant improvements in strength.
Muscle size
This systematic review provides equivocal evidence to
substantiate the impact of ES on muscle size because of the
small number of studies and conflicting results. Of the two
studies that provided measures of thigh muscle size, cor-
rected thigh circumference was modestly increased in
one28 while the other did not find any improvement in thigh
mass evaluated by DEXA.24 Similar to the associated factors
to muscle function, the different level of impairment of the
subjects enrolled in these two studies might have contrib-
uted to the different response in muscle hypertrophy
observed. Participants who showed improvement were
malnourished patients with a very low BMI (18  2.4 and
18.1  2.6)28 whereas the other study had patients with
moderate COPD and higher baseline exercise capacity.
Thus, benefit from ES might be optimized when applied to
muscles with higher initial levels of atrophy.33
Differences in the parameters of stimulation might also
account for the different hypertrophic responses observed.
The study in which muscle mass increased,28 used higher
intensities (15e90 mA) and lower frequencies (5e35 Hz)
compared to the study that showed no change (10e45 mA
and 50 Hz respectively). In addition, the different designs of
the training programs (i.e., dosage, frequency, duration),
might have contributed to the differences in hypertrophic
responses. At present, the optimal parameters of stimula-
tion to increase muscle mass in these patients are unknown.
Other studies investigating muscle hypertrophy after
resistance training in patients with COPD have shown similar
increases in muscle mass (0.20; 95% CI 0.02e0.43) to those
obtained after ES (0.10; 95% CI1.05e0.85).28 These results
suggest that, regardless of the type of intervention, large
increases in muscle bulk after training are not easily ach-
ieved for these patients. Given the conflicting reports of
muscle hypertrophy in response to ES,24,28 and the small
effect size of both resistance training and ES, it would
appear that muscle growth may not only depend upon the
effectiveness of the intervention but also on other individual
characteristics such as nutritional and hormonal status.58
Muscle fibre characteristics
Only one study examined fibre characteristics so no meta-
analyses were performed on these outcomes. Of interest,
ES induced a preferential increase in the cross sectional
Electrical stimulation and muscle function in COPD 493area of type II fibres and a decrease in the cross sectional
area of type I fibres that did not translate into improvement
of muscle mass or muscle function.24 Hypertrophy of type II
fibres might be explained by the preferential recruitment
of these motor units during ES,59 however, not all studies
have shown a greater involvement of these motor units60,61
or greater type II hypertrophy53 after ES. Another potential
explanation might be due to a greater potential for
hypertrophy since these fibres showed type II specific
atrophy at baseline.24 Given the relative atrophy of fast
twitch fibres in COPD10e13 as well as the greater hypertro-
phic capacity of these fibres,62 their larger growth after ES
is not surprising.Exercise performance
The pooled randomeffect of ES onwalking distancewas 47 m
with 95% CI 9.08e86.01, (Fig. 3) similar to the commonly
reported minimal clinically important difference of 54 m
(95% CI 37e71) for the 6-min walking test.63 Thus, despite
variable gains in muscle performance in four
studies,23,25,26,28 the effects of ES on this functional test are
modest. A fourth study reported that ES increased time to
exhaustion in a constant work rate cycling test,23 another
reflection of improved muscle endurance. Similar to
outcomes of muscle strength, participants in the two studies
that demonstrated improvements in walking distance or
endurance time after ES23,26,28 had more severe disease
whereas the participants in the one study that had no
improvement had moderate disease24 (Table 2 and Fig. 3).
Study limitations
The main limitation of this review is the small number of
studies analysing ES in this population group. Due to the
small sample size and the heterogeneity of outcomes,
meta-analyses of all outcomes could not be performed. The
lack of standardization of ES protocols further confounds
comparisons between studies. These methodological
differences might explain some of the conflicting results
revealed by the studies.
Another limitation of this review is that only one author
performed the literature search and selection of the
studies. Thus, the possibility of selection bias cannot be
completely discarded. The selection of articles, however, is
likely complete because the articles examined for this
systematic review are similar to those described in
a recently published narrative review.48Conclusions and implications for future research
Despite being attractive as a therapeutic intervention, the
moderate effect sizes in most outcomes suggest that the
effectiveness of ES to improve lower limb muscle function in
individuals with COPD needs to be considered carefully. ES
produces modest benefits of muscle function and exercise
performance such as peak torque and walking distance. Due
to the paucity of evidence assessing hypertrophy, the effec-
tiveness of ES to increasemusclemass is unclear. ES seems to
favour specific hypertrophic changes in fast muscle fibres.However, the functional implications of these adaptations
remain equivocal. It would appear that more impaired
patients seem to respond more effectively to ES, however,
whether ES can be used as an adjunct of resistance or
endurance training, or as an intervention in the initial phases
of training after immobilization requiresmore investigations.
Further studies with larger sample sizes are needed to
determine the clinical effectiveness of this therapy. A crit-
ical aspect in future studies will be to elucidate optimal
parameters of ES and types of patients that might benefit
from this technique. The appropriate selection of patients
with impaired muscle function might be crucial to maximize
the benefits of this technique. COPD is a chronic diseasewith
multiple manifestations and the use of ES needs to be eval-
uated on a case-by-case basis. When ES is considered, the
level of muscle impairment is possibly the most important
indicator to take into account.
The specificity of ES possibly reduces transfer of strength
improvements to functional tasks compared to more voli-
tional training (i.e., skill training) involving more complex
movements that produce adaptations in higher neurological
structures (i.e., cortical structures) related to motor control
and task learning. In this regard, recent studies have
confirmed ‘‘experience-specific patterns of plasticity’’ in the
nervous system.64 In other words, the specific neural adap-
tations resulting from any physical activity depend on the
specific task being performed during this activity. According
to this principle, the transferability of gains in muscle
performance observed after ES to functional tasks might be
limited. In support of this, clinical trials investigating the
impact of resistance training on exercise performance in
patients with COPD49 have reported similar results to those
obtainedafter ES, thus confirming that transferability of gains
from muscle function to exercise performance is moderate.
In summary, although ES has the potential to be used as
an adjunct to rehabilitation of the more able patients, it
seems to be more appropriate as a primary intervention in
critical care situations when the patient is being confined
to bed rest. Otherwise, ES may not offer special advantages
over more volitional training.
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